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Abstract 
Background: HIV and malaria exert co-pathogenic effects. Malaria surveillance data are necessary for public health 
strategies to reduce the burden of disease in high HIV prevalence settings.
Methods: This was a longitudinal cohort study to assess the burden of malaria in rural Rakai, Uganda. Households 
were visited monthly for 1 year to identify confirmed clinical malaria (CCM), or parasitaemia with temperature 
>37.5 °C, and asymptomatic parasitaemia (AP). Interviews of the adult or child’s caregiver and clinical and laboratory 
assessments were conducted. Rapid diagnostic testing for malaria and anaemia was performed if participants were 
febrile and anti-malarial treatment given per Uganda Ministry of Health 2010 guidelines. Blood was drawn at every 
household visit to assess for parasitaemia, and blood smears were assessed at the Rakai Health Science Programme 
laboratory.
Results: A total of 1640 participants were enrolled, including 975 children aged 6 months up to 10 years, 393 adult 
caregivers, and 272 adolescent/adult household members from 393 randomly selected households in two repre-
sentative communities. 1459 (89 %) participants completed all study visits. CCM was identified in 304 (19 %) partici-
pants, with the highest incidence rate for CCM of 0.38 per person-year (ppy) identified in children <5 years, and rates 
decreased with age; the rates were 0.27, 0.16, and 0.09 ppy for ages 5–<10 years, 10–<18 years, and adults 18+ years, 
respectively. AP was identified in 943 (57 %) participants; the incidence rate was 1.99 ppy for <5 years, 2.72 ppy for 
5–<10 years, 2.55 ppy for 10–<18 years, and 0.86 ppy among adults, with 92 % of cases being attributed to Plasmo-
dium falciparum by smear. 994 (61 %) individuals had at least one positive smear; 342 (21 %) had one positive result, 
203 (12 %) had two, 115 (7 %) had three, and 334 (21 %) had >3 positive smears during follow-up. Seasonal rates 
generally followed the rains and peaked during July, then decreased through November before increasing again.
Conclusions: Plasmodium falciparum infection remains high in rural Uganda. Increased malaria control interventions 
should be prioritized.
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Background
Malaria is a leading cause of morbidity and mortality in 
Uganda, accounting for 25–40  % of all outpatient vis-
its at health facilities, 20  % of hospital admissions, and 
9–14 % of inpatient deaths [1]. Children under 5 years and 
pregnant women and HIV-infected individuals bear the 
greatest burden of disease [2]. Malaria incidence data for 
this period of time are lacking for most areas of Uganda, 
particularly in areas of high HIV prevalence, with the most 
recent Malaria Indicator Surveys having published data 
collected in 2009 [1] and 2014–2015 [3]. Because HIV 
and malaria exert co-pathogenic effects [4], malaria sur-
veillance data are necessary for public health strategies to 
reduce the burden in high HIV prevalence settings. The 
rural district of Rakai, Uganda, has an HIV prevalence of 
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9 % (age 15–59 years. cf. national prevalence of 7.3 %) [5]. 
A study of malaria among children with fever in a hospital 
setting in the rural Rakai district, Uganda was conducted 
by this research team and previously described high preva-
lence of malaria parasitaemia and anaemia among children 
under 5 years [6]. Because of the continued transmission 
potential that exists with subclinical parasitaemia, and 
because many patients do not have ready access to treat-
ment in rural areas, a complementary active-surveillance 
study was conducted to determine population-based rates 
of malaria parasitaemia and clinical malaria in Rakai Dis-
trict, and to describe the clinical presentation and preven-
tion strategies being used in households for malaria. This 
report describes the characteristics of malaria in this rural 
community with high HIV prevalence [7].
Methods
Rakai district is on a plateau at an altitude ranging 
between 750 and 900 m and has fair rainfall throughout 
the year, with relatively dry periods during January and 
February and from June through August. Peak rainfall 
varies from year to year, but occurs typically in March/
April and October/November [8]. Malaria is meso- to 
holo-endemic with year round transmission and high-
est intensity following the rainy seasons or in communi-
ties adjacent to lakes and other mosquito breeding sites. 
Specifically, the Rakai district has high transmission with 
estimates preceding this study of more than 100 infec-
tive bites per person per year [1]. This was a longitudinal 
household cohort study, with active-surveillance visits by 
clinicians every 4 weeks during a 1 year follow-up period 
for each household. The study period spanned from 
April 2011–September 2012, which included a 6  month 
recruitment period of randomly selected households 
from two communities in Rakai District. The communi-
ties and households were identified from the Rakai Com-
munity Cohort Study (RCCS) described elsewhere [9].
RCCS household enumeration census data were 
used to identify households with two or more children 
between the age of 6  months and 10  years. A statisti-
cian from RHSP randomly selected eligible households 
from the census data. A study nurse approached house-
holds on each list sequentially to provide information 
about the surveillance study to the primary caregiver, 
and then screened the household for eligibility. The 
study recruited: the primary caregiver of children from 
each household; all eligible children aged 6 months up to 
10 years; and one additional adult or adolescent partici-
pant aged 14 years or older. Due to limited resources the 
study team was unable to recruit every individual in each 
household; therefore, one additional adult/adolescent 
participant was randomly selected among eligible adult/
adolescents in the household using the Kish grid method 
[10]. This recruitment method employs a pre-assigned 
table of random numbers to identify a respondent within 
each household unit with the aim to reduce selection 
bias.
Study visits were made to enrolled households every 
4  weeks during a 1  year surveillance period. Visit pro-
cedures included: structured interview of the primary 
caregiver or legal guardian of the children, clinical and 
laboratory assessment of each participant in the house-
hold, and a heel/finger stick for blood smear; slides were 
read at a later time at the Rakai Health Sciences Program 
(RHSP) laboratory. If a participant was febrile (>37.5 °C) 
the study team also performed a rapid diagnostic test 
and hemoglobin to assess the need to treat for malaria or 
anemia. Referrals were made for severe malaria to local 
clinics for care. Anemia was defined as any hemoglobin 
level <11 g/dl, and further characterized for comparabil-
ity with the Uganda MIS reports as mild (10–10.9 g/dl), 
moderate (8–9.9 g/dl), or severe (<8 g/dl). Data collected 
during the structured interview included self-reported 
use of malaria prevention methods, including indoor 
residual spray, mosquito bed net, insecticide-treated bed 
net and intermittent preventive treatment.
Confirmed clinical malaria (CCM) was defined as evi-
dence of parasitaemia (positive RDT or smear), accom-
panied by signs/symptoms consistent with malaria, 
specifically axillary temperature >37.5 °C. Treatment for 
malaria was provided according to the Ugandan Minis-
try of Health (MOH) guidelines [11] which include arte-
misinin combination therapy for uncomplicated malaria. 
Severe malaria was defined in accordance with the World 
Health Organization (WHO) guidelines [12], with local 
modifications due to laboratory constraints, as Plasmo-
dium falciparum parasitaemia of any level (or positive 
RDT) plus one or more of the following: hemoglobin 
<5  g/dl, prostration, respiratory distress, bleeding, mas-
sive haemoglobinuria, recent seizures, coma or obtun-
dation, inability to eat or drink, persistent vomiting or 
jaundice. Participants identified with suspected severe 
malaria were referred immediately for in-patient treat-
ment at the nearest health center or hospital.
Statistical methods
This study is a descriptive, non-comparative study to 
assess the epidemiology of malaria infection in chil-
dren aged 6  months–<10  years, and adults living in 
same households as children. The main objective is to 
estimate the incidence of asymptomatic and sympto-
matic malaria in the study population in preparation for 
future malaria studies in Rakai, including malaria vac-
cine trials. As data was lacking on malaria incidence in 
Rakai communities, and on the variance in children aged 
6 months–<10 years, sample size calculations were based 
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on a method [13] that applies a pre-determined ratio 
between the precision width and the standard deviation 
to estimate sample sizes for descriptive studies using the 
formula N  =  4z2S2/W2. A precision width that is 10  % 
of the standard deviation is narrow enough to provide a 
large enough sample size that would adequately describe 
the incidence of malaria in the study population. Using a 
95 % confidence interval (CI) and a ratio of interval width 
to standard deviation (W/S) of 0.10 requires a total sam-
ple size of 1537 participants. A low loss to follow-up rate 
of 3 % was assumed and by adjusting for a non-response 
rate of 3  %, the required total sample size was deter-
mined to be 1635 [1537/(1–0.06)] participants. The unit 
of enrolment was the household; therefore, an adequate 
number of households were enumerated from RCCS cen-
sus data using known household age cohort structure 
within these Rakai communities in order to approximate 
this sample size. Malaria prevalence is reported as pro-
portion of subjects identified during the study period 
with CCM or AP and stratified by subject characteristics, 
including age, sex and community. A Chi square statistic 
was used to compare prevalence across age and gender 
strata. Incidence estimates are reported per person-year 
with 95 % CI. A kappa statistic was calculated to measure 
the level of agreement between RDT and blood smear 
findings. The malaria attributable fraction (MAF) among 
febrile subjects is also reported along with 95  % CI for 
these estimates to provide a measure of the proportion 
of fevers identified during this study period which can be 
attributed to malaria. All analyses were conducted using 
SAS software version 9.4. Copyright, SAS Institute Inc. 
SAS and all other SAS Institute Inc. product or service 
names are registered trademarks or trademarks of SAS 
Institute Inc., Cary, NC, USA.
Laboratory procedures
Laboratory evaluations included the following at all 
scheduled surveillance visits: Hemocue® rapid haemo-
globin test for febrile subjects and malaria rapid diagnos-
tic test (Malaria Total Quick Test, Cypress Diagnostics, 
Langdorp, Belgium, sensitivity 99.7  % and specificity 
99.5 %.) for febrile subjects; thick and thin slide malaria 
smears were obtained from all subjects by finger- or heel-
prick and evaluated in the RHSP laboratory. The malaria 
“Total Quick” RDT tests for both antigens specific to P. 
falciparum (HRP2) as well as lactate dehydrogenase, 
which is an antigen shared by other Plasmodium species 
that infect humans, including P. falciparum, Plasmodium 
ovale, Plasmodium malariae, and Plasmodium vivax. 
Thick smears were used to identify parasites and quantify 
parasite count. Thin smears were used for parasite specia-
tion. All slides were read in the RHSP Lab by experienced 
microscopists who were blinded to the history or signs of 
clinical malaria. Internal quality assurance of smear reads 
was conducted by preserving slides and having a separate 
blinded microscopist reread 10  % of all slides with any 
discrepant resolved by a third microscopist.
Ethics
The study was approved by the Uganda Virus Research 
Institute Science and Ethics Committee, the Uganda 
National Council for Science and Technology, and the 
National Institute of Allergy and Infectious Diseases 
Intramural Institutional Review Board. All study partici-
pants at least 18 years of age provided written informed 
consent prior to screening. Parents or guardians of 
minors provided written consent and children aged 
8 years and older provided assent to the research.
Results
The primary caregivers in 403 households were vis-
ited in their homes and provided information about the 
study, of which 393 (98 %) agreed to participate. Of the 
ten households not enrolled, four caregivers refused par-
ticipation, three caregivers were unable to be contacted, 
two households had all children away at boarding school, 
and one household had migrated out of the study area. 
A total of 1640 participants were enrolled, including 393 
(24 %) adult caregivers, 975 (59 %) children <10 years of 
age, and 272 (17  %) other adult or adolescent members 
of the households. An average of 2.5 child participants, 
and an average of 4.2 total participants, were enrolled 
per household. Table 1 presents a summary of enrolment 
characteristics.
Retention in the annual surveillance study was high 
with 1459 (89  %) of participants completing the final 
study visit. Visit adherence was also very high, with only 
481 (2.2 %) of 21,618 expected study visits missed; 21,137 
(97.8  %) participant visits were completed during the 
surveillance period. 108 (6.6  %) participants were lost 
to follow-up, twenty-two (1.3  %) participants withdrew 
consent, and there were four (0.2 %) deaths. Forty-seven 
(2.9  %) of participants were terminated due to other 
circumstances.
There were 21,128 blood smears obtained during the 
study period. CCM was identified in 304 (19  %) par-
ticipants (Table  2), with highest proportion of CCM 
in children <5  years (33  % for males; 25  % for females, 
p  <  0.0001). CCM prevalence decreased with age, with 
the lowest rate identified among adult females (7  %). 
The rate of CCM was consistently higher among males 
than females in all age categories (p  <  0.0001). AP was 
identified in 943 (57  %) participants during the study 
period. The prevalence of AP was highest in older chil-
dren (5–<10  years) and adolescents (10–<18  years) and 
lowest in children under five and adults (18+ years). The 
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prevalence of AP did not differ by gender among children 
<10  years; however, in older children, adolescents and 
adults, males had ~10 % higher proportion of AP within 
each age stratum.
Incidence rate estimates for malaria are presented 
according to age and gender strata (Table  3). Overall 
incidence of CCM in this study was 0.23 per person-year 
(ppy). Rates of CCM follow the same general trend as for 
prevalence, with youngest children <5 years bearing the 
greatest burden of malaria (0.38 ppy), and decreasing 
rates of malaria with increasing age (0.27 ppy in children 
5–<10 years, 0.16 ppy in ages 10–<18 years, and 0.09 ppy 
in adults 18+). Incidence of AP was 1.99 ppy overall, and 
remained high across all age cohorts: the rate estimate 
is 1.99 ppy in young children <5  years, 2.72 in children 
5–<10 years, 2.55 ppy in ages 10–<18 years, and 0.86 ppy 
in adults 18+.
Figure 1 shows the frequency of positive smear results 
(any level of parasitaemia) during the study period. 646 
(39 %) had no positive smears; 994 (61 %) individuals had 
at least one positive smear of which 342 (21 %) had one 
positive result, 203 (12 %) had two, 115 (7 %) had three, 
Table 1 Enrollment by community, cohort and gender
Kalisizo n (%) Kabira n (%) Total n (%)
Male Female Male Female
Cohort
 Caregivers 07 (2) 202 (51) 05 (1) 179 (46) 393 (24)
 Children  
< 10 years
292 (30) 231 (24) 235 (24) 217 (22) 975 (59)
 Additional adult/
adolescents
77 (28) 62 (23) 66 (24) 67 (25) 272 (17)
 Total 376 (23) 495 (30) 306 (19) 463 (28) 1640
Table 2 Prevalence of confirmed clinical malaria and asymptomatic parasitaemia by age and gender
Age (years) Confirmed clinical malaria n (%) Asymptomatic parasitaemia n (%) Total participants n (%)
Male Female Male Female Male Female Total
0.5–<5 76 (33) 45 (25) 128 (56) 104 (58) 229 (56) 179 (44) 408 (25)
121 (30) 232 (57)
05–<10 68 (23) 52 (19) 196 (66) 169 (63) 298 (53) 269 (47) 567 (35)
120 (21) 365 (64)
10–<18 13 (13) 15 (14) 71 (72) 68 (61) 99 (47) 111 (53) 210 (13)
28 (13) 139 (66)
18+ 7 (12) 28 (7) 31 (55) 176 (44) 56 (12) 399 (88) 455 (28)
35 (8) 207 (45)
Total 164 (24) 140 (15) 426 (62) 517 (54) 682 (42) 958 (58) 1640
304 (19) 943 (57)
Table 3 Incidence rate (per person-year) of confirmed clinical malaria and asymptomatic parasitaemia by age and gender
CI confidence interval
Age (years) Confirmed clinical malaria (95 % CI) Asymptomatic parasitaemia (95 % CI)
Male Female Male Female
0.5–<5 0.43 (0.34, 0.51) 0.32 (0.23, 0.40) 1.97 (1.64, 2.29) 2.01 (1.58, 2.44)
0.38 (0.32, 0.44) 1.99 (1.72, 2.25)
05–<10 0.29 (0.23, 0.35) 0.26 (0.19, 0.33) 2.86 (2.55, 3.17) 2.56 (2.21, 2.91)
0.27 (0.23, 0.32) 2.72 (2.47, 2.97)
10–<18 0.19 (0.11, 0.27) 0.13 (0.08, 0.19) 2.70 (2.19, 3.20) 2.43 (1.95, 2.90)
0.16 (0.12, 0.21) 2.55 (2.20, 2.90)
18+ 0.17 (0.07, 0.28) 0.08 (0.05, 0.11) 1.22 (0.92, 1.52) 0.81 (0.70, 0.93)
0.09 (0.06, 0.12) 0.86 (0.75, 0.96)
Total 0.31 (0.27, 0.35) 0.18 (0.15, 0.21) 2.40 (2.19, 2.61) 1.70 (1.54, 1.85)
0.23 (0.21, 0.26) 1.99 (1.86, 2.11)
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and 334 (21  %) had >3 positive smear results during 
follow-up.
Figure  2 shows monthly prevalence of smear posi-
tive malaria outcomes during the study period. Seasonal 
rates generally followed the rains [8] and peaked during 
April to July, then decreased through November before 
increasing again.
There were speciation results for 3267 positive smear 
readings. Plasmodium falciparum was identified in 92 %, 
P. vivax in 6 %, and P. malariae in 6 % of smears. The pre-
dominance of P. falciparum was parallel in both clinical 
malaria and asymptomatic parasitemia groups (Table 4). 
There were 113 instances of multi-species infection, with 
72 (2  %) cases identified with both P. falciparum and P. 
vivax; 40 (1  %) cases, with both P. falciparum and P. 
malariae; and one (0.03 %) case with both P. vivax and P. 
malariae.
Fever (temperature of >37.5  °C) was identified at 467 
(2.2  %) visits. 468 rapid diagnostic tests for malaria were 
performed in febrile participants and 347 (74.2  %) RDT 
samples were positive. Subsequent confirmation of these 
results by thick smear showed 242 (52 %) smear-positivity. 
There were concordant positive results for 218 (47 %) sam-
ples, concordant negative results for 113 (24  %) samples, 
and discordant results for 137 (29 %) samples: eight (2 %) 
samples were RDT-negative but smear-positive, and 129 
(28  %) samples were RDT-positive, but smear-negative. 
The kappa statistic for level of agreement between RDT 
and smear result was 0.42 (95 % C.I. 0.35, 0.49).
The malaria attributable fraction among febrile epi-
sodes was consistent across age groups: 67  % among 
young children <5  years, 68  % in children 5–<10  years, 
66 % in ages 10–<18 years, and 70 % in adults 18+ years. 
There was a notable difference between genders that was 
consistent across all age groups, with males demonstrat-
ing a higher fraction of fevers attributable to malaria. 
The MAF for fever among male participants was 76  %, 
whereas for females it was 58 %.
Prevalence of anaemia was determined for all febrile 
participants and results are presented in Table  5 only 
Fig. 1 Frequency of positive smears for each participant during 
follow-up data value for each bar is number (%) of participants
Fig. 2 Malaria prevalence and average rainfall by month. bar rainfall* (mm), lower line clinical malaria, upper line asymptomatic parasitaemia. *mean 
historical monthly rainfall data for Rakai, Uganda during 1990–2009 was accessed on May 12, 2015 from The World Bank Group Climate Change 
Knowledge Portal: http://sdwebx.worldbank.org/climateportal/index.cfm?page=country_historical_climate&ThisRegion=Africa&ThisCCode=UGA
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for participants <10  years since anaemia was very rare 
in older age groups. Among 336 children <10 with fever, 
122 (36 %) showed anaemia of any severity level, of which 
113 (93  %) had CCM. All 20 children identified with 
severe anaemia (hemoglobin < 8 g/dl) were CCM cases, 
and CCM cases were 3.86 times more likely to be anae-
mic compared to children without CCM (p  <  0.0001). 
Younger children <5  years were 1.84 times more likely 
to be anaemic compared to older children 5–<10  years 
(p < 0.0001).
Self-reported (or caregiver-reported for children) 
prevention methods used at baseline are summarized 
in Table  6. 192 (12  %) participants reported use of 
indoor residual spray (IRS) in the household, 656 (40 %) 
reported use of any mosquito bed net, of which 473 
(29  %) reported the bed net was an insecticide-treated 
net (ITN), and 31 (2 %) reported using intermittent pre-
ventive treatment (IPT) for malaria. Caregivers reported 
using bed nets more frequently than other cohorts 
(p < 0.001).
Discussion
This study describes the relatively high rates of malaria 
in rural Uganda that also has a high burden of HIV [7]. 
This is compatible with other studies in rural Uganda. A 
strength of this study is the longitudinal monthly assess-
ments at the household level among a large number of 
individuals over a 1  year period and across a spectrum 
of age groups. Loss to follow-up was minimal and adher-
ence was high. The study provides estimates of malaria 
incidence rather than prevalence alone, and during a 
time frame in rural Uganda not described by the peri-
odic MIS rounds. Furthermore, the study also provides 
information on malaria prevention methods, and reports 
on prevalence of anaemia among febrile children. There 
are some important limitations of this study. Recruit-
ment targeted households from two community clusters 
within Rakai district that provided convenient access to 
the study team due to their proximity to health centers 
and therefore these findings might not be generalizable 
to the entire district. The investigators did not ascertain 
HIV sero-status as part of the study; however, we these 
results are interpretable within the context of an area of 
known endemic HIV transmission and prevalence.
Findings from this study are consistent with reports 
from the Uganda MIS from 2009 to 2014/2015 (Rakai 
District is included in the Central 1 region), which show 
a downward trend for prevalence of malaria and anaemia 
Table 4 Speciation observed for positive smears (N = 3267)
Multiple species were identified for 113 positive smears, so the total count shows as higher than the number of positive slides





Plasmodium falciparum 220 (7) 2778 (93) 2998 (92)
Plasmodium malariae 3 (2) 193 (98) 196 (6)
Plasmodium vivax 10 (5) 176 (95) 186 (6)
Table 5 Prevalence of anemia among children age 6 months–<10 years
Severe anemia (<8 g/dl) 
n (%)
Moderate anemia  
(8–9.9 g/dl) n (%)






 0.5–<5 15 (8) 26 (15) 41 (23) 95 (54) 177 (53)
 05–<10 5 (3) 21 (13) 14 (9) 119 (75) 159 (47)
Gender
 Male 14 (7) 25 (13) 30 (16) 119 (63) 188 (56)
 Female 6 (4) 22 (15) 25 (17) 95 (64) 148 (44)
Cluster
 Kalisizo 7 (4) 29 (17) 31 (18) 103 (61) 170 (51)
 Kabira 13 (8) 18 (11) 24 (14) 111 (67) 166 (49)
Confirmed clinical malaria status
 Yes 20 (8) 41 (16) 52 (20) 144 (56) 257 (76)
 No 0 (0) 6 (8) 3 (4) 70 (89) 79 (24)
 Total 20 (6) 47 (14) 55 (16) 214 (64) 336
Any anaemia 122 (36)
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in young children age 0–59  months. The current study 
from 2011/2012 is in between these MIS time points, 
and prevalence estimates for CCM in the youngest age 
cohort likewise fall in between (30  % in this study, ver-
sus 45 % from the MIS in 2009 and 13 % in 2014/2015). 
Prevalence of anaemia follows a similar trend, with 8  % 
of the youngest age cohort from the current study iden-
tified with severe anaemia (hemoglobin  <  8  g/dl), com-
pared to 11 and 4 % respectively from the MIS 2009 and 
2014/2015; and 46 % of children <5 years from this study 
identified with any level of anaemia (hemoglobin < 11 g/
dl) compared to 63 % form the MIS 2009. Reported use 
of malaria prevention strategies in the current study is 
also comparable to the Uganda MIS findings. Overall 
use of any mosquito bed net (40 %) and ITN (29 %) fall 
in between an apparent increasing trend reported in MIS 
(any bed net use in children was 32 % in 2009 and 68 % in 
2014/2015, with use of ITN 22 % for children <5 years in 
2009, and 59 % in 2014/2015).
As expected, the predominant species identified by 
microscopy was P. falciparum. The identification of P. 
vivax in East Africa is not unexpected, although this iden-
tification was done by smear and not by PCR. The pres-
ence of P. vivax in Duffy-negative individuals, as would be 
expected in East Africa, has been previously described in 
East Africa [14] and in the Amazon [15]. It is also possible 
that the specificity of microscopy was not optimal.
The discrepancy between RDT and smear positivity is 
also not unexpected but is higher than has been observed 
in other studies [1, 3]: for the 2  % of samples that were 
RDT negative but smear positive, it is possible that non-
falciparum species accounted for the RDT “false nega-
tives” since the sensitivity for non-falciparum species 
with this RDT is slightly lower. Indeed, for those eight 
(2 %) discordant samples of the samples we reported on, 
six (75 %) were positive for P. falciparum, one (12 %) was 
positive for P. vivax, and one (12  %) was positive for P. 
malariae. For the 28  % of RDTs that were positive but 
smear negative, it is possible that microscopy sensitivity 
was imperfect, or that the RDTs were picking up circulat-
ing antigen or parasites (gametocytes) that existed after 
patients had been recently treated for infection [16].
A higher degree of AP than CCM was observed in this 
study. If molecular methods had been employed in this 
study, we likely would have detected higher AP rates. 
Indeed, using sensitive molecular methods and targeting 
interventions to those with AP is important to eradica-
tion since it likely fuels the cycle of transmission. Com-
munity-wide drug treatment, indoor residual spraying, 
bed net distribution, and mosquito larviciding are all 
efforts that have been and could be guided by highly sen-
sitive community screening and intervention efforts [17].
It is likely that children who had febrile illnesses who 
were RDT negative had infections other than malaria, 
and this has been increasingly described in the litera-
ture recently. In fact, recent studies have shown that 
with the decreasing incidence of malaria as evidenced 
by data in this study and the Uganda MIS 2009 and 
2014/2015 [1, 3], etiologies of fever in younger chil-
dren are much more likely to be due to viral illnesses 
than bacterial or parasitic infections (such as typhoid 
or malaria) [18].
Conclusions
Plasmodium falciparum infection remains high in rural 
Rakai, Uganda. Increased malaria interventions should 
be implemented to reduce the burden of disease.
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